Long-term results of rituximab–intravenous immunoglobulin combination therapy in patients with epidermolysis bullosa acquisita resistant to conventional therapy

References

• Elliot GT. Two cases of epidermolysis bullosa. J Cutan Genitourin Dis. 1895;13:10.
   Google Scholar
• Zhu XJ, Niimi Y, Bystryn JC. Epidermolysis bullosa acquisita. Incidence in patients with basement membrane zone antibodies. Arch Dermatol. 1990;126:171–4.
   PubMedGoogle Scholar
• Ishii N, Hamada T, Dainichi T, et al. Epidermolysis bullosa acquisita: what's new? J Dermatol. 2010;37:220–30.
   PubMed Web of Science ®Google Scholar
• Gupta R, Woodley DT, Chen M. Epidermolysis bullosa acquisita. Clin Dermatol. 2012;30:60–9.
   PubMed Web of Science ®Google Scholar
• Ludwig RJ. Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita. ISRN Dermatol. 2013;2013:812029.
   PubMedGoogle Scholar
• Gurcan HM, Ahmed AR. Current concepts in the treatment of epidermolysis bullosa acquisita. Expert Opin Pharmacother. 2011;12:1259–68.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim YH, Kim SC. Epidermolysis bullosa acquisita: a retrospective clinical analysis of 30 cases. Acta Derm Venereol. 2011;91:307–12.
   PubMed Web of Science ®Google Scholar
• Mohr C, Sunderkotter C, Hildebrand A, et al. Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins. Br J Dermatol. 1995;132:824–6.
   PubMed Web of Science ®Google Scholar
• Segura S, Iranzo P, Martinez-de Pablo I, et al. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. J Am Acad Dermatol. 2007;56:960–7.
   PubMed Web of Science ®Google Scholar
• Schmidt E, Benoit S, Brocker EB, et al. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol. 2006;142:147–50.
   PubMedGoogle Scholar
• Saha M, Cutler T, Bhogal B, et al. Refractory epidermolysis bullosa acquisita: successful treatment with rituximab. Clin Exp Dermatol. 2009;34:e979–80.
   PubMed Web of Science ®Google Scholar
• Daniel BS, Hertl M, Werth VP, et al. Severity score indexes for blistering diseases. Clin Dermatol. 2012;30:108–13.
   PubMed Web of Science ®Google Scholar
• Morbach H, Eichhorn EM, Liese JG, Girschick HJ. Reference values for B cell subpopulations from infancy to adulthood. Clin Exp Immunol. 2010;162:271–9.
   PubMed Web of Science ®Google Scholar
• Kazkaz H, Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol. 2004;4:398–402.
   PubMed Web of Science ®Google Scholar
• Arin MJ, Hunzelmann N. Anti-B-cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus – an update. Eur J Dermatol. 2005;15:224–30.
   PubMed Web of Science ®Google Scholar
• Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol. 2005;153:620–5.
   PubMed Web of Science ®Google Scholar
• Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31:456–73.
   PubMed Web of Science ®Google Scholar
• Peterson JD, Chan LS. Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: a comprehensive survey of 71 consecutive patients from the Initial use to 2007. Ther Clin Risk Manag. 2009;5:1–7.
   PubMedGoogle Scholar
• Colliou N, Picard D, Caillot F, et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med. 2013;5:175ra30.
   PubMed Web of Science ®Google Scholar
• Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007;56:3044–56.
   PubMed Web of Science ®Google Scholar
• Crichlow SM, Mortimer NJ, Harman KE. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol. 2007;156:194–6.
   PubMed Web of Science ®Google Scholar
• Niedermeier A, Eming R, Pfutze M, et al. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol. 2007;143:192–8.
   PubMedGoogle Scholar
• Sadler E, Schafleitner B, Lanschuetzer C, et al. Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. Br J Dermatol. 2007;157:417–19.
   PubMed Web of Science ®Google Scholar
• Mercader P, Rodenas JM, Pena A, Mascaro JM. Jr, Fatal Pseudomona pneumonia following rituximab therapy in a patient with epidermolysis bullosa acquisita. J Eur Acad Dermatol Venereol. 2007;21:1141–2.
   PubMed Web of Science ®Google Scholar
• Wallet-Faber N, Franck N, Batteux F, et al. Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab. Dermatology. 2007;215:252–5.
   PubMed Web of Science ®Google Scholar
• Cavailhes A, Balme B, Gilbert D, Skowron F. Successful use of combined corticosteroids and rituximab in the treatment of recalcitrant epidermolysis bullosa acquisita. Ann Dermatol Venereol. 2009;136:795–9.
   PubMed Web of Science ®Google Scholar
• Kubisch I, Diessenbacher P, Schmidt E, et al. Premonitory epidermolysis bullosa acquisita mimicking eyelid dermatitis: successful treatment with rituximab and protein A immunoapheresis. Am J Clin Dermatol. 2010;11:289–93.
   PubMed Web of Science ®Google Scholar
• Li Y, Foshee JB, Sontheimer RD. Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease. J Am Acad Dermatol. 2011;64:773–8.
   PubMed Web of Science ®Google Scholar
• McKinley SK, Huang JT, Tan J, et al. A case of recalcitrant epidermolysis bullosa acquisita responsive to rituximab therapy. Pediatr Dermatol. 2014;31:241–4.
   PubMed Web of Science ®Google Scholar
• Brassat S, Fleury J, Camus M, et al. Epidermolysa bullosa acquisita and graft-versus-host disease. Ann Dermatol Venereol. 2014;141:369–73.
   PubMed Web of Science ®Google Scholar
• Meissner C, Hoefeld-Fegeler M, Vetter R, et al. Severe acral contractures and nail loss in a patient with mechano-bullous Epidermolysis bullosa acquisita. Eur J Dermatol. 2010;20:543–4.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee SE, Kim SC. Successful treatment of epidermolysis bullosa acquisita with rituximab therapy. J Dermatol. 2012;39:477–9.
   PubMed Web of Science ®Google Scholar
• Kolesnik M, Becker E, Reinhold D, et al. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication. J Eur Acad Dermatol Venereol. 2014;28:771–80.
   PubMed Web of Science ®Google Scholar
• Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol. 2001;45:679–90.
   PubMed Web of Science ®Google Scholar
• Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol. 2001;45:825–35.
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Sami N. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. J Am Acad Dermatol. 2002;46:42–9.
   PubMed Web of Science ®Google Scholar
• Sami N, Letko E, Androudi S, et al. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology. 2004;111:1380–2.
   PubMed Web of Science ®Google Scholar
• Czernik A, Toosi S, Bystryn JC, Grando SA. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update. Autoimmunity. 2012;45:111–18.
   PubMed Web of Science ®Google Scholar
• Jolles S. A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. Clin Exp Dermatol. 2001;26:127–31.
   PubMed Web of Science ®Google Scholar
• Lolis M, Toosi S, Czernik A, Bystryn JC. Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies. J Am Acad Dermatol. 2011;64:484–9.
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Gurcan HM. Treatment of epidermolysis bullosa acquisita with intravenous immunoglobulin in patients non-responsive to conventional therapy: clinical outcome and post-treatment long-term follow-up. J Eur Acad Dermatol Venereol. 2012;26:1074–83.
   PubMed Web of Science ®Google Scholar